 | |
| Clinical data | |
|---|---|
| Trade names | Disalcid, Salflex |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682880 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.008.208 |
| Chemical and physical data | |
| Formula | C14H10O5 |
| Molar mass | 258.229 g·mol−1 |
 N Y (what is this?) (verify) | |
Salsalate is amedication that belongs to thesalicylate andnonsteroidal anti-inflammatory drug (NSAID) classes.
Salsalate is the generic name of a prescription drug marketed under thebrandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[1]
Relative to other NSAIDs, salsalate has a weak inhibitory effect on thecyclooxygenase enzyme and decreases the production of several proinflammatorychemical signals such asinterleukin-6,TNF-alpha, andC-reactive protein.[2]
The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition ofIκB kinase resulting in decreased action ofNF-κB genes.[2][3][4] This mechanism is thought to be responsible for salsalate'sinsulin-sensitizing andblood sugar lowering properties.[3]
Salsalate may be used for inflammatory disorders such asrheumatoid arthritis or noninflammatory disorders such asosteoarthritis.[2][5]
The risk ofbleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated withaspirin use.[3]
Salsalate has been proposed for the prevention and treatment oftype 2 diabetes mellitus due to its ability to lowerinsulin resistance associated with inflammation and may be useful inprediabetes.[2] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[2]
Salsalate had been suggested as possible treatment for diabetes as early as 1876.[2][6][7]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
